BioSpace News Archive

Quest Diagnostics announced today financial results for the third quarter ended September 30, 2017.

Dynavax Technologies Corporation announced initiation of dosing in a phase 1B dose escalation clinical trial of its investigational inhaled toll-like receptor 9 (TLR9) agonist, DV281, in patients with non-small cell lung cancer (NSCLC).

Cellect announced today that it has nominated Dr. Ronit Bakimer-Kleiner as Chief Development Officer replacing Dr. Yaron Pereg.

Vitality Biopharma, a corporation dedicated to the development of cannabinoid prodrug pharmaceuticals, and to unlocking the power of cannabinoids for the treatment of serious neurological and inflammatory disorders, today announced additional positive preclinical efficacy results for the treatment of colitis.

Kent’s device is the next step in perfusion imaging by directly showing tissue oxygenation.

Thermo Fisher Scientific today announced the commercial launch of the Applied Biosystems Axiom Africa Array for medical and population genomics to accelerate and support initiatives in global health and population research.

PTC Therapeutics today announced that the Company will host a webcast conference call to report its third quarter financial results and provide an update on the company’s business and outlook on Thursday, November 2, 2017 at 4:30 p.m. (ET) after the closing of the market.

The company plans to expeditiously advance AMT-061 instead of AMT-060.

CRH Medical plans to release its unaudited results for the quarter ended September 30, 2017, on Wednesday, November 1, 2017 after market close.

GIMDx announced today that it has concluded an exclusive OEM and International Distribution agreement for IncellDx single cell immune-oncology and oncology diagnostic products in China.